Saturday, May 30, 2026 U.S. Edition · Independent
Markets
CMPS 13.00 ▲ 9.06%
ATAI 4.57 ▲ 3.63%
GHRS 23.78 ▲ 6.26%
AXSM 233.72 ▲ 0.38%
NBIX 158.06 ▲ 1.07%
ACAD 21.82 ▲ 0.88%
LLY 1095.92 ▼ 2.74%
JNJ 226.73 ▼ 1.76%
ABBV 216.57 ▼ 0.94%
CURLF 3.56 ▲ 12.66%
GTBIF 8.01 ▲ 5.67%
TCNNF 9.67 ▲ 14.62%
VRNO 1.19 ▲ 6.25%
TLRY 5.59 ▼ 1.06%
CGC 1.11 ▼ 0.89%
MSOS 5.04 ▼ 1.56%
MJ 27.18 ▼ 0.18%
TDOC 7.94 ▲ 5.73%
HIMS 26.16 ▲ 3.07%
TALK 5.20 ▲ 0.19%
LFMD 4.37 ▼ 4.79%
ACHC 23.26 ▼ 2.10%
UHS 149.49 ▼ 0.42%
CMPS 13.00 ▲ 9.06%
ATAI 4.57 ▲ 3.63%
GHRS 23.78 ▲ 6.26%
AXSM 233.72 ▲ 0.38%
NBIX 158.06 ▲ 1.07%
ACAD 21.82 ▲ 0.88%
LLY 1095.92 ▼ 2.74%
JNJ 226.73 ▼ 1.76%
ABBV 216.57 ▼ 0.94%
CURLF 3.56 ▲ 12.66%
GTBIF 8.01 ▲ 5.67%
TCNNF 9.67 ▲ 14.62%
VRNO 1.19 ▲ 6.25%
TLRY 5.59 ▼ 1.06%
CGC 1.11 ▼ 0.89%
MSOS 5.04 ▼ 1.56%
MJ 27.18 ▼ 0.18%
TDOC 7.94 ▲ 5.73%
HIMS 26.16 ▲ 3.07%
TALK 5.20 ▲ 0.19%
LFMD 4.37 ▼ 4.79%
ACHC 23.26 ▼ 2.10%
UHS 149.49 ▼ 0.42%

Research

Coverage of academic research, clinical trials, and methodological developments across mental health.

How to read a psychedelic Phase 3 trial: a methods primer

An evergreen reference on what actually matters in a psychedelic-assisted therapy trial readout — blinding analyses, expectancy controls, dose-response designs, and the questions to ask before you trust the headline number.